Aligos Therapeutics (ALGS) Retained Earnings (2021 - 2025)
Historic Retained Earnings for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$622.3 million.
- Aligos Therapeutics' Retained Earnings fell 1612.61% to -$622.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$622.3 million, marking a year-over-year decrease of 1612.61%. This contributed to the annual value of -$618.0 million for FY2024, which is 2695.32% down from last year.
- Aligos Therapeutics' Retained Earnings amounted to -$622.3 million in Q3 2025, which was down 1612.61% from -$590.8 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Retained Earnings registered a high of -$202.4 million during Q1 2021, and its lowest value of -$622.3 million during Q3 2025.
- In the last 5 years, Aligos Therapeutics' Retained Earnings had a median value of -$440.9 million in 2023 and averaged -$435.0 million.
- Per our database at Business Quant, Aligos Therapeutics' Retained Earnings plummeted by 6733.03% in 2022 and then plummeted by 1020.13% in 2025.
- Quarter analysis of 5 years shows Aligos Therapeutics' Retained Earnings stood at -$303.1 million in 2021, then tumbled by 31.68% to -$399.1 million in 2022, then decreased by 21.97% to -$486.8 million in 2023, then decreased by 26.95% to -$618.0 million in 2024, then dropped by 0.7% to -$622.3 million in 2025.
- Its Retained Earnings stands at -$622.3 million for Q3 2025, versus -$590.8 million for Q2 2025 and -$574.9 million for Q1 2025.